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The longitudinal associations between endothelial function and diabetes type II and 
diabetes related outcome in people with no major non-communicable chronic diseases: a 
systematic review 
Mahrukh Jamil, Concordia University 
Context: Endothelial function plays a very important role in controlling vascular tone, 
inflammatory responses, immune responses and haemostasis. It has been linked with the 
progression of diabetes type II in the literature, but its directionality is still unknown. Also, there 
are no systematic reviews available on this topic. Objective: To explore whether endothelial 
function is associated with type II diabetes and other diabetes related outcomes in apparently 
healthy participants with no non-communicable diseases using a systematic review. Data 
sources: PubMed, Scopus and Web of Science databases were searched, from inception to 
September 2019, for articles published in English and French. Search terms include synonyms of 
diabetes type II, HbA1c, endothelial function, flow-mediated dilation and finger 
plethysmography. Study selection: Longitudinal studies and cohort/placebo/control group of 
interventions studies with non-invasive endothelial function measures—flow mediated dilation 
(FMD) and reactive hyperemia index (RHI)—at the start of the study and a diagnosis of type II 
diabetes or any surrogate measure of diabetes at follow-up were included. Data Extraction: 
Data extraction and quality assessment using Newcastle-Ottawa scale for cohort studies were 
performed by the two reviewers independently. Data synthesis: Qualitative data synthesis was 
performed. Result: The search yielded 20141 retrieves, 12429 articles were obtained after 
deduplication, out of which 127 were screened for full text, 16 selected articles were used for 
data extraction and author’s contact. Four articles were included for final analysis. Three studies 
reported a non-significant relationship between endothelial function and fasting plasma glucose 
and HbA1c; whereas one study reported significant results for endothelial function and incidence 
of diabetes. Conclusion: The available evidence from this review did not show any statistically 
significant association between endothelial function (measured by FMD and RHI) at baseline 
and surrogate measures of diabetes type II (fasting blood glucose, HbA1c) but showed limited 
evidence(with only one article) that endothelial function at baseline is associated with the 
diagnosis of type II diabetes. More longitudinal studies with healthy participants having primary 
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C.I: Confidence interval 
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The endothelium is the mono-cellular layer that lines the blood and lymphatic vessels. It is a 
paracrine, endocrine and autocrine organ that lines the entire vascular system of the body 
including heart and capillaries (1). Endothelial cells being the inner most layer of cells is the first 
line of defense that comes into contact with blood. Hence, endothelial function is the main 
facilitator of various tasks that regulates the functionality of blood as well the vascular function 
of the vessels such as vasodilation and vasoconstriction. The endothelium is responsible for other 
major functions including but not limited to; control of hemostasis, inflammatory response and 
permeability of the blood (2). More specifically, the endothelial cells:  
• Act as a barrier by selectively allowing macro molecules and solute to cross from the 
blood to interstitial fluid and vice versa (3, 4). Hence, they facilitate transportation of 
macro and micro molecules like glucose, amino acid, proteins and ions (5). 
• Control the tone of smooth muscle cells by releasing various mediators that produce 
vasoconstrictors like endothelin, prostaglandins and angiotensin II, that maintains a 
balance between vasodilation and vasoconstriction (6).  
• Regulate the production of calcium-dependent enzyme nitrous oxide synthase (NOS) that 
is responsible for the nitrous oxide that plays an important role in vascular tone (5, 7, 8). 
• Act as key regulators of the inflammatory response. Inflammation is the body’s defense 
response against foreign invading particles. It involves killing of the invading microbes 
and removing the debris (9). Leukocytes are the responder of the inflammation. 
Endothelial cells produce many signals that actively take part in migration of leukocytes 
and hence facilitates the inflammation process (10). Leukocytes migrate from the blood 
into the tissue for immune response by binding to the endothelial cell adhesion 
molecules.   
• Start a cascade of actions to form cross linked stable clots to perform haemostasis 
(1). Haemostasis refers to the body’s physiological response to the excessive blood flow 
to injury or unusual circumstances. The vessel provides action to prevent excessive 
bleeding and hemorrhage by producing clots (11). Endothelial cells play a vital role in 
haemostasis with the assistance of lumen of the vessel, platelets, coagulation and 
fibrinolytic systems. They also perform necessary action to dissolve the clot later when it 
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is not required anymore (8). Similarly, physiological fluidity of the blood is also 
controlled by the endothelium. It prevents the formation of thrombus by activating anti 
coagulation processes (12). 
 
1.1.Endothelial Dysfunction: 
Endothelial dysfunction is a broad term that encompasses dysregulation and malfunctioning of 
endothelial cell functions (13). This disruption causes an imbalance of vasodilation and 
vasoconstriction functioning resulting in unbalanced transport of blood flow, irregular vasal tone, 
anti-coagulation, anti-fibrinolysis and disturbed haemostasis (14). Endothelial dysfunction is the 
representation of the bad health of endothelium. Poor endothelial function is associated with the 
progression of plaque formation and other vascular complications (15). Reactive oxygen species 
(ROS) are one of the documented causes of endothelial dysfunctions. ROS can disrupt the 
production of nitrous oxide, leaving the endothelium vulnerable to toxins and infections making 
it overly permeable (16). Diminished activity of nitrous oxide can lead to inhibited endothelial 
signaling which can result in many chronic diseases, including cardiovascular disease. There are 
many factors that are associated with an increase in the prevalence of endothelial dysfunction 
including but not limited to: a sedentary lifestyle and a lack of physical activity, smoking and 
alcohol consumption, metabolic syndrome, and diabetes (17). 
Previous studies have shown a strong relationship between endothelial dysfunction and coronary 
diseases (18) and it has been identified as a risk marker for atherosclerosis and cardiovascular 
risk factors (17, 19). Several systematic reviews and meta-analysis have been conducted to 
predict cardiovascular risk and other adverse outcomes from non-invasive measures of 
endothelial function (20-23). This not only shows the prognostic power of endothelial function to 
predict adverse outcomes but also relates how endothelial dysfunction is responsible for many 
vascular complications including atherosclerosis, cardiovascular diseases and diabetes.  
1.2.Measurement of Endothelial Function: 
Endothelial function is measured with either invasive or non-invasive methods. Non-invasive 
methods mostly focus on changes in the peripheral artery due to the production of NO (nitrous 
oxide) when external pressure is applied (24). It has been shown that endothelial function being 
measured, within peripheral arteries (brachial artery or ulnar/finger artery) is similar in 
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magnitude and direction as that of larger arteries, suggesting that peripheral techniques are 
adequate substitutes (25, 26). Some of the commonly used non-invasive methods are; flow 
mediated dilation, peripheral arterial tonometry (PAT) and forearm hyperemic reactivity (FHR) 
(25, 27). 
These non-invasive measures are reported as a good substitute of invasive measures for several 
reasons. Firstly, the methods to conduct the invasive measures are quite expensive and 
complicated (28). Also, due to their invasive nature, they cannot be applied to larger populations 
making it only suitable for research purpose but not for clinical and prognostic use (29). Several 
studies have reported that the direction and, to a reasonable extent, the magnitude of changes in 
peripheral arteries (brachial artery or ulnar/finger artery) in response to external shear stress is 
comparable to changes seen in larger conduit (coronary) arteries (30). Non-invasive measures 
(such as flow mediated dilation (FMD) or RHI) have also been used extensively in the literature 
to predict risk of adverse outcomes such as cardiovascular future outcomes and other mortality 
causes. (22, 23, 25-27). All these aspects provide reasonable evidence that these non-invasive 
measures can be considered as reasonable substitutes for more invasive measures. 
The most common non-invasive method is FMD (23). It uses a method of providing temporary 
pressure to the forearm to induce a hyperemic environment. In response to this stimulus, there is 
an increase in nitrous oxide release into the blood stream. Increased nitrous oxide production 
leads to more vasodilation that can be measured as changes in the diameter of the brachial artery 
and an increase in regional blood flow. Dysfunction of the endothelium is evident from an 
impaired response, i.e., FMD (31). It is common to define the FMD response as the percentage 
change of brachial artery diameter from pre-hyperemia to 60 seconds post-hyperemia (32). The 
brachial artery blood flow response is usually measured using ultrasound imaging (23). Although 
it is the most common method, several factors such as placement of pressure cuff, control of 
environmental factors like room temperature, caffeine intakes, probe position and human error 
are some of the aspects that can cause variations hence decreases its reliability (33). Another 
technique, peripheral arterial tonometry (PAT) utilizes the finger plethysmography method of 
recording pulse wave amplitude (PWA) to measure the pulsatile changes in the volume of blood 
in the finger (34). PWA is recorded before and during the hyperemia (35). The PWA ratio is 
calculated which is an average of PWA between pre and post occlusion (36). EndoPat is a 
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patented method that provides beat to beat blood flow volume measures utilizing the changes in 
the volume of finger arterial pressure (37). This technique has shown high reproducibility of 
results as this is a much simpler procedure than other non-invasive techniques (38). Forearm 
hyperemic reactivity (FHR) is another non-invasive method to measure endothelial function. It 
uses a radiotracer to measure FMD and compare the reactive arm with a reference arm after 
inducing temporary hyperemia (39).  Dynamic images are acquired using a gamma camera with 
high resolution. The acquired images are then compared with the reference arm images to 
calculate the parameters of endothelial function like relative uptake ratio (RUR) and elbow to 
wrist uptake ratio(EWUR) (40). FHR has shown some advantages over FMD as it has shown 
better test retest reliability and inter-rate reliability (r=0.98) (41). Using the radiotracer eases the 
process and can be performed during the same session as other myocardial perfusion test (42). 
One of the commonly used invasive method of endothelial function is to measure the plasma 
levels of biomarkers that activates the endothelium or is produced by it; such as soluble 
intercellular adhesion molecules (s-ICAM), plasminogen activator, von Willebrand factors 
(vWF) etc. (43) However, for functional quantification, clinicians prefer non-invasive method as 
the production of these biomarkers are not just endothelium specific but other factors, such as 
inflammation, can also influence it. It has also been suggested that a single biomarker is not 
enough but multiple biomarkers that are representative of the underlying disease (endothelial 
dysfunction) must be used for prognostic purpose (28, 44).  The preferred method by clinicians is 
the non-invasive method as it depend on the functional changes in endothelium without inserting 
anything inside the body and its clinical utility is more diverse (29, 45).  
1.3.Diabetes type II: 
Diabetes mellitus is a series of metabolic diseases which are characterized by the presence of a 
hyperglycemic environment inside the body. It reflects an ineffective production or consumption 
of insulin by the body. Insulin plays an important part in glucose concentration regulation and 
diabetes type II is characterised by insulin resistance or relative insulin deficiency (46). It is more 
prevalent than type I diabetes with almost 90% of cases having diabetes type II out of the total 
diabetic population. Some of the factors that increase the risk of diabetes type II are; genetic 
factors or family history, obesity, imbalanced diet, age 40 or above, high levels of blood 
cholesterol, hypertension and history of gestational diabetes. There is no specific cure for 
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diabetes except keeping the blood glucose in control which can be achieved initially with 
changes in health behaviour like increased physical activity and consumption of low carb diet, 
and then by medication are prescribed. Some of the common pharmacological medication are 
metformin, thiazolidinediones, sulfonylureas, sodium-glucose transporter (SGLT) 2 inhibitors, 
meglitinides, glucagon-like peptide-1 receptor agonists (GLP-1 receptor agonists), dopamine 
agonist and alpha-glucosidase inhibitors (47).   
According to the World Health Organization (WHO), the number of reported cases of diabetes 
has quadrupled since 1980. A 2016 Global WHO report noted 422 million diabetic cases world-
wide (48). In Canada, there has been a 70% increase in prevalence of reported diabetic cases 
over the decade between 1998-2008 (49). As of 2019, 11 million people were reported to be 
living with diabetes or prediabetes in Canada, with type 2 diabetes accounting for 90 to 95 
percent of these cases. According to the statistics provided by Canadian Diabetes Association, 
the percentage of Canadians living with diabetes or prediabetes will rise to 33 percent by 2025, if 
current trends continue (50). Diabetes also increases the chances of other chronic diseases. 36.5 
% of Canadians with diabetes reported having other chronic diseases like hypertension, 
cardiovascular diseases and mood disorders (51). 
Diabetes itself is not the main cause of mortality but it gives rise to many vascular complications, 
including but not limited to vasculopathy such as nephropathy, neuropathy and retinopathy as 
well as cardiovascular diseases and atherosclerosis (52, 53). It is estimated that almost 60% of 
patients with diabetes die because of cardiovascular disease (54). Diabetic neuropathy affects 
different parts of the nervous system that could give rise to sensory or autonomic neuropathies 
(55). These neuropathies augment substantial morbidity and can cause mortality. More than 80% 
of amputations are caused by foot ulceration and injuries in diabetic patients (56). Diabetic 
retinopathy, end stage renal failure, and chronic kidney diseases are some other common 
complications of diabetes (57). 
1.4.Methods of measuring Diabetes type II: 
The status of diabetes is usually defined by blood based levels of hemoglobinA1c (HbA1c) and 
levels of glucose in blood/plasma in fasting and non fasting conditions (58). Official clinical 
diagnosis is made through the HbA1c test and oral glucose tolerance test (OGTT).  
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The HbA1c complex is formed by non-enzymatic, irreversible binding of glucose residue 
molecules with the hemoglobin which depend upon the level of glucose concentration inside the 
blood. In a diabetic environment, the increase of plasma glucose gives rise to more glucose 
binding with hemoglobin and hence it can be detected (59, 60). The average life span of an 
erythrocyte is 3 months (120 days) which automatically makes the duration of presence of 
glycated hemoglobin in the body as 3 months. It is due to this reason that HbA1c test is seen 
reliable for assessing the presence of long term or lasting hyperglycemic environment in the 
body (61). According to Diabetes Canada guidelines, a hemoglobin A1c level of 6% to 6.4% is 
considered prediabetes and 6.5% and above as diabetes (62). 
The oral glucose test relies on the ability of an individual’s gastronomical absorption of glucose. 
The individual is given a load of 75 grams of glucose either orally or intravenously and plasma 
glucose is measured after 2 -hours for the random plasma glucose concentration test (63). The 
individual must fast for at least 8 hours before this test, so the fasting glucose tolerance test is 
usually conducted early in the morning. According to the guidelines of the Diabetes Canada, 
presence of diabetes can be identified, if the plasma glucose level is equal to or more than 7.0 
mmol/L for an 8 hour fasting test and equal to or greater than 11.1 mmol/L for post 2-hour 
glucose tolerance test after the administration of 75 gram glucose (64).  
1.5.Relationship between Endothelial function and Diabetes type II: 
There are a number of publications, in the form of reviews, observational and trial-based studies, 
that have explored the relationship between endothelial function and diabetes type II. Since 
endothelium is responsible for the transport of micro and macro molecules, it is also responsible 
for insulin resistance as it does not only transport insulin products to the tissues but it’s also the 
target site for the actions of insulin. Insulin resistance can in turn give rise to other complications 
like hypertension, dyslipidemia and diabetes type II (65, 66). Similarly, the condition of 
neuropathy that is commonly present in diabetes, is also reported to be occurring in case of 
endothelial dysfunction irrespective of serum glucose concentration (67). Endothelial 
dysfunction causes damage to the peripheral nerves by inhibition of some glycolytic enzymes 
that initiate various inflammatory pathways which causes an imbalance between redox state and 
ROS (68) . It can be concluded that increased ROS and pro-inflammatory responses are 
responsible for diabetic neuropathy, caused as a result of endothelial dysfunction. Likewise, the 
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endothelial dysfunction of renal microcirculation leads to albuminuria in people without any 
diagnosed renal disease. Albuminuria was reported to be related to the incidence of diabetes in 
men in the epidemiological study of insulin resistance syndrome, providing a potential link 
between endothelial dysfunction and increased diabetes incidence (69).  
The inflammatory cascade response within endothelial cells in response to pathological stimuli 
are mediated by cellular adhesion molecules (CAMs) and their expression. Several risk factors of 
the endothelium such as atherogenesis and hypercholesteremia, increase oxidative stress and 
affect the production of CAMs (70). Increased levels of CAMs facilitate leukocytes adhesion and 
migration through the endothelial junctions causing endothelial dysfunction. Hence endothelial 
dysfunction has been linked to be the early marker of pathological processes leading to 
cardiovascular disease and diabetes type II (71).  
Studies have shown that a hyperglycemic environment also gives rise to increased production of 
ROS. It was concluded by the author that the production of reactive oxygen species depletes the 
reserves of antioxidants under high glucose condition, a logical explanation of augmentation of 
ROS under the manifestation of hyperglycemia (72). ROS are also responsible for the reduced 
bioavailability of nitrous oxide and other vasoconstricting and dilating factors that skew the 
balance towards vasoconstriction during the progression of diabetes (73). These molecules 
increase the intercellular gap formation causing impaired cell to cell adhesion thus increasing 
permeability. Increased permeability and ROS levels are also evidence of endothelial 
dysfunction (74). These facts point towards the possibility of worsening of the endothelial 
dysfunction as a result of diabetes. 
On the contrary, many studies support the claim that endothelial dysfunction is the initiator of 
diabetes type II (17, 18, 74, 75). Though the literature consists of strong evidences supporting 
either of the directionality of causation of these two conditions, i.e., endothelial dysfunction and 
diabetes type II, it has still not come to a unifying conclusion for the cause and direction of this 
association. It is also evident from the literature that both the conditions of diabetes type II and 
endothelial dysfunction have many common mechanisms and physiological processes. Thus, this 
confusion in the literature and co-dependent biological processes has made it tough to make a 
conclusive statement about the association between endothelial function and diabetes type II. A 
great number of studies present in the literature on this topic are cross sectional in nature. Since 
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they measure the exposure and incidence at the same time point, they cannot be used to establish 
a temporal sequence. To our knowledge, no systematic review has been conducted to explore the 
association between endothelial dysfunction and the development of diabetes. Therefore, a need 
for the exploration of this relationship longitudinally at least in one direction, so that we could 
move one step closer in affirming the order of sequence of events as they occur and a temporal 
sequence between the two could be established. Thus, this review focuses on exploring the 
association of poor endothelial function giving rise to the future development of diabetes type II.  
The choice of  non-invasive methods used for the measurement of endothelial function for this 
systematic review was guided by the fact that they are regarded as easier and safer methods by 
clinicians (27, 29, 76) Since invasive measures require specialized equipments to conduct the test 
and due to its invasive nature, it is not suitable for all patient population. Also, the biomarkers of 
endothelial function are influenced by mechanisms and factors other than endothelium that 
diminishes its prognostic power. Therefore, this review focuses only on the studies which 
employ a non-invasive method for measurement of the same. It must be noted that both of the 
conditions (endothelial dysfunction and diabetes type II) results in grave complications and 
chronic diseases and leads to financial burden on the economy as well. That’s why it is important 
to establish the directionality of this association, so that the healthcare professionals can plan and 
take necessary therapeutic steps to intervene and prevent the progression of any potential 































The main motivation behind this thesis was to systematically explore the relationship between 
endothelial function and the development of diabetes type II in healthy individuals who don’t 
have any other NCDs. The specific objectives of this systematic review were: 
1. Explore the longitudinal association between endothelial function when measured at 
baseline in healthy adult participants with no non-communicable chronic disease and the 
incidence of diabetes type II at follow up.  
2. Explore the longitudinal association between endothelial function when measured at 
baseline in healthy adult participants with no non-communicable disease, and diabetes-
based outcome measures (i.e. fasting or random plasma glucose and HbA1c) at follow up. 
 
2.1. Hypotheses: 
We hypothesized the following:  
1. Poor endothelial function, defined as smaller values of FMD or RHI, will be associated 
with a greater incidence of diabetes (as defined by either the Diabetes Canada guidelines 
(77) or physician diagnosed or use of diabetes medication) in healthy adult without any 
non-communicable disease. 
2. Poor endothelial function, defined as smaller values of FMD or RHI, would be related to 
a worsening of surrogate diabetes measures, defined as increased fasting blood glucose 
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Objective: A systematic review of the longitudinal association between endothelial function 
(when measured at baseline) and the incidence of diabetes or its surrogate markers (when 
measured at a follow up) in apparently healthy participants with no non-communicable diseases. 
Background: Endothelial function plays a very important role in controlling vascular tone, 
inflammatory responses, immune responses and haemostasis and its dysregulation can cause 
diabetes type II.  
Method: PubMed, Scopus and Web of Science databases were searched, from inception to 
September 2019, for relevant articles in English and French. Longitudinal studies and 
cohort/placebo/control group of interventions studies with non-invasive endothelial function 
measures—flow mediated dilation (FMD) and reactive hyperemia index (RHI)—at the start of 
the study and a diagnosis of type II diabetes or any surrogate measure of diabetes at follow-up 
were included. Studies using biomarkers of endothelial function, in-vitro or animal studies were 
excluded along with thesis, reviews, reply and comments or editorial articles. Acceptable 
outcomes were either diagnosis of diabetes type II or its surrogate markers. Data extraction and 
quality assessment (using relevant sections of the Newcastle-Ottawa scale for cohort studies) 
were performed by the two reviewers (MJ and TT) independently. Data was summarized based 
on the analysis information available from four included studies. 
Result: A Total of 20,141 retrieves, resulting into 12,429 after duplicate removal, out of which 
125 were screened for full text. 16 articles were selected for inclusion, data extraction and 
author’s contact. Out of four included articles, three studies reported a non-significant and one 
reported a significant relationship between endothelial function and incidence of diabetes. 
Conclusion: The evidence that emerged from this review did not show any association between 
endothelial function  )measured by FMD and RHI) at baseline and surrogate measures of diabetes 
type II (measured by fasting blood glucose, HbA1c). There appears to be limited evidence that 
endothelial function at baseline is associated with the diagnosis of type II diabetes. More 
longitudinal studies with healthy participants having primary focus on this association are 
required to provide more evidence in this domain. 
Registration key: CRD42018091662 (https://www.crd.york.ac.uk/PROSPERO/#recordDetails) 
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The endothelium is a mono-cellular layer that acts as a paracrine, endocrine and autocrine organ 
as well as a semipermeable layer that is affected by mechanical and chemical stimuli (1, 78). 
Endothelial cells, being the first point of contact with blood, perform some crucial functions, 
including regulation of blood flow and smooth muscle cell tone through vasoconstrictors and 
vasodilators (2, 4), regulation of the production of Calcium-dependent enzyme nitrous oxide 
synthase (NOS) which in turn is responsible for the yield of nitrous oxide that plays an important 
role in vascular tone (5, 7, 8). Endothelial cells also play an effective role in homoeostasis and 
inflammation (2, 10-12). Any dysregulation resulting in dysfunction of these endothelial cells 
causes an imbalance in vasodilation and vasoconstriction, which affects the transport and flow of 
blood. It may also cause imbalance in vessel tone, anti-coagulation, anti-fibrinolysis and 
disturbed hemostasis (11, 13, 79).  Endothelial dysfunction is manifested quite early in the 
process of atherogenesis (80). The development of a series of metabolic diseases characterized 
by the prevalence of hyperglycemic environment inside the body, is referred to as Diabetes 
Mellitus (55), which is characterizes with insulin deficiency (46, 81). Vascular complications 
such as nephropathy, neuropathy and retinopathy, atherosclerosis and cardiovascular diseases are 
the most common complications of diabetes (52, 82).  
Since the endothelium is functionally responsible for the transport of materials throughout the 
vascular network of the body, including insulin, several studies have explored the potential role 
of endothelial dysfunction in the insulin resistant condition (65). Endothelium not only facilitates 
in the transport of insulin product but also acts as a target site for its action. The vasodilatory 
response of insulin on skeletal muscles is mediated by endothelium dependent nitrous oxide 
production. Therefore, both the endothelial function and insulin exhibit a nature of codependence 
on each other (83). A previous study by Pinkney suggested that the endothelial dysfuntion at the 
capillary level becomes a precursor of insulin resistance and its related complications while in 
larger arteries causes artherosclerosis (65). It is reported that insulin resistance proves to be the 
antecedent of many serious vascular complications and diabetes type II because of the same 
reason.  
Similarly, in the presence of a chronic stressful mechanical or chemical stimuli, the endothelial 
cells alters their regulation by increasing the biochemical expression of different mediators and 
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molecules (67). They give rise to pro-inflammatory repsonses, imbalanced redox and reactive 
oxygen species and increased glycolysis (68, 84). This pathway provides a potential link between 
endothelial dysfunction and diabetes type II. Some cross-sectional studies have reported inverse 
correlations between diabetes surrogate markers, fasting blood glucose (FBG) and HbA1c, and 
endothelial function measures (FMD) in non diabetic population (85, 86). Likewise, it was 
reported in the drug trials that the medications prescribed for the correction of endothelial 
dysfunction also decreases the incidence of diabetes type II (87-89). All these physiological 
processess and studies shows a plausiable link between endothelial function and its progression 
towards diabetes type II. Furthermore, a number of studies have explored the hypothesis that 
diabetes type II and cardiovascular diseases originate from “common soil” as they have similar 
environmental antecedent (13, 79).  
Although the available literature supports the association between endothelial function and 
diabetes type II, these association are mostly cross-sectional, and, it is unclear if there is a 
consistent longitudinal association between endothelial function and the progression to diabetes 
type II. As such, the primary objective of this study was to systematically review longitudinal 
studies in the literature published thus so far to determine if an association exists between 
endothelial function and diabetes type II in healthy adults. The review was built around the 
following PECO statement: P= Adults with no non-communicable disease (NCDs); E= poor 
baseline endothelial function; C= normal baseline endothelial function; O= Diabetes type II. We 
hypothesized that poor endothelial function (when measured with non-invasive methods) at 
baseline would be associated with diabetes type II or increased surrogate markers of diabetes at 
follow-up in adults with no other major non-communicable chronic diseases.  
3.2.Methods: 
3.2.1. Protocol and Registration: 
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (90) was 
used to formulate and develop the protocol for this systematic review (see appendix 2 for the 
PRISMA checklist). This systematic review is registered with PROSPERO (CRD42018091662). 
3.2.2. Eligibility Criteria: 
18 
 
Longitudinal studies (cohort or control/placebo arms of longitudinal intervention-based studies) 
of apparently healthy adult participants were included. Apparently healthy adult participants 
were defined as individuals aged 18 or older with no other major non-communicable chronic 
disease (NCDs defined by presence of stenosis, current unstable angina or exertional ischemia, 
history of revascularization (bypass, PTCA, or stent), myocardial infarction, stroke, peripheral 
vascular disease, cancer, chronic obstructive pulmonary disease (COPD) and rheumatoid 
arthritis)) and with no other life threating diseases. Studies published in English or French 
language were included. Studies must have used a non-invasive and functional method of 
endothelial function measurement at baseline, specifically flow-mediated dilation (FMD) or 
finger plethysmography defined with reactive hyperemia index (RHI). To be included in the 
review, following measures of diabetes were regarded as acceptable outcomes: incident diabetes 
(self-reported after diagnosed by physician), any medication use of diabetes type II, fasting blood 
glucose or HbA1c levels defined as diabetic according to Diabetes Canada guidelines (49). 
The studies which reported endothelial function measures through biomarkers like iCAM, 
vCAM etc. were excluded as the biomarkers are not produced by endothelium only but effected 
by other factors such as inflammation, etc. Animal and in-vitro studies, along with, theses, 
reviews, comments and editorial papers were also excluded. 
3.2.3. Search Strategy: 
Three databases, PubMed, Web of Science and Scopus, were searched for relevant references 
through September 2019. The search terms consisted of keywords built around the concepts of 
endothelial function and diabetes type II, their synonyms and measures. In addition, NOT terms 
of ‘Animal’ and ‘Review’ were also employed. The electronic search strategy was designed in 
PUBMED and adapted to other databases (see Appendix 3 for full details). The first search was 
run on 18 Sep 2018 on all 3 databases, yielding a total of 18,877 articles. It was updated twice; 
once in March 2019 and another on 28 September 2019, which generated an additional 1264 
articles making a total of 20,141 articles.  
3.2.4. Study Selection: 
The study selection was conducted in two phases. In phase one, articles were screened for titles 
and abstracts. In the second phase, full text articles were screened and kept if they met all the 
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inclusion criteria. This review was conducted by two reviewers (MJ and TT). In case of any 
disagreement between the two reviewers, a third reviewer (SLB) was consulted to reach a 
consensus.  
3.2.5. Data Extraction: 
After reading the full articles, only the articles that fulfill the inclusion criteria were kept for data 
extraction. The extraction of data focused on two aspects: general information about the article; 
and the specific data regarding the research question. The general data included: First author; 
journal name; year of publication; inclusion and exclusion criteria; study design; duration of the 
study; and duration of follow-up. The specific data included: sample size; sex distribution; age of 
the population; endothelial function measure used; mean and standard deviation of endothelial 
function at baseline; diabetic measures used; and mean and standard deviation of diabetes 
measures at follow up. If any analysis were reported between the endothelial function and 
diabetic measures, they were also extracted and noted in the extraction table. Multivariate 
analysis (Beta and standard error) of the relationship between endothelial function at baseline 
and measures of diabetes (adjusted for age and sex) were requested from authors if not available 
in the primary publication. 
3.2.6. Quality assessment and Risk of bias: 
Relevant sections of the Newcastle-Ottawa scale for cohort studies (91) was used for the quality 
assessment as has been done previously (92). We only rated the studies out of 6 question instead 
of 8, and skipped the question dealing with non-exposed cohort and comparability of cohorts as 
it did not apply to our systematic review. Each question had a selection of four multiple choice 
options. A maximum of one star and a minimum of zero stars can be given for each question. 
The higher the number of stars, can be defined as a good quality study with a lower risk of bias. 
Conversely, studies can be defined as fair and poor based on the awarded stars and show a higher 
risk of bias (91). Each of the final selected studies (n=4) were assessed by two reviewers 
independently (MJ and TT). In case of a difference of opinion between the two reviewers, the 
third reviewer (SB) was consulted. The original Newcastle-Ottawa scale for cohort studies can 
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3.3.1. Study Selection: 
Two reviewers (MJ and TT) independently and simultaneously screened 12,419 articles based on 
the abstract and titles after duplicate removal. A total of 127 articles were reviewed for full text 
out of which 16 articles made it to final inclusion for which data was extracted independently by 
both reviewers (MJ and TT). The authors of 15 studies were contacted for more information 
specifically for analysis between endothelial function and diabetes measures. They were given 
one-month to respond (with two reminder emails sent during this time period). Six authors 
responded but only three of them provided useful data for inclusion in the systematic review. In 
total, four articles were included in the systematic review. The study selection is summarized in 
the PRISMA (90) flow diagram in figure 1 above. 
3.3.2. Characteristics of Selected Studies:  
Of the four studies included, two were longitudinal cohort study design (93, 94) and the other 
two were comparison groups of longitudinal intervention studies (95, 96). The characteristics of 
the studies are summarized in table 1. Two of the studies had only male participants (95, 96)and 
two studies have female-only population (93, 94). The follow-up duration of each included study 
was different. Endothelial function was measured by either flow-mediated dilation (FMD) or the 
reactive hyperemia index (RHI) or both. Either Fasting blood glucose (FBG) and HbA1c or both 
were used to denote diabetic measures in three of the studies. The study by Rossi et al. (94) 
measured fasting blood glucose at every follow up. However, they reported the outcome with 
incidence of diabetes. The incidence was determined with either FBG levels for diabetes 
diagnosis or self reported medication use or physician diagnosis.
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Table 1. Characteristics of the Selected Studies 
Study Design Population 
Age  
Mean years 















Joris et al 
(2017) (95) 
RCT Control group of 
Healthy males 
52 (45.4-61.1) * 26 Male 2.0 FMD, RHI FBG 
Ostlund et al. 
(2013) (93) 
Cohort Healthy women with a 
history of 










RCT Placebo group of 
Young men with 
obesity 
34.3 (1.1) 30 Male 6.0 RHI FBG, 
HbA1c 




53.0 (6.0) 840 female 46.8 (8.4) FMD Incidence 
of 
diabetes 




3.3.3. Flow mediated dilation and Fasting blood glucose: 
Two studies (93, 95) provided data on the relation between baseline FMD and FBG at follow up. 
While the study by Joris et al (95) had data on a single cohort, the study by Ostlund et al. (93) 
provided data on two cohorts; population 1 consisted of women with a history of preeclampsia 
where as population 2 had healthy women. The multivariate analysis (adjusted for age and sex) 
for all three-cohorts (table 2) showed that there was no significant relationship between baseline 
FMD and FBG at follow up. Nonetheless, the beta coefficient in two cohorts indicated a positive 
relationship between baseline FMD and FBG, i.e., an increase in FMD value (better endothelial 
function) was related to increased value of FBG (increase chances of diabetes which goes against 
our hypothesis). Out of the three cohorts, one cohort (population 1 women with history of 
preeclampsia) of the Ostlund et al. (93) showed a negative correlation between FMD and FBG 
which is in line with our hypothesis. 












Joris et al. 
(2017) (95) 
FMD FBG 26 00.02 00.05 0.731 
Ostlund et al. 




FMD FBG 15 -33.93 63.89 0.600 
Ostlund et al. 
Control Pop 
2(2013) (93) 
FMD FBG 15 23.02 65.06 0.730 
* adjusted for age and sex, FMD: flow mediated dilation, FBG: Fasting blood glucose, RHI: 
reactive hyperemia index, pop: population  
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3.3.4. Reactive hyperemia index, fasting blood glucose and HbA1c: 
Two studies reported the relation between RHI and FBG (95, 96). The multivariate analysis 
(adjusted for age and sex) for both cohorts (table 3) showed that there was no significant 
relationship between baseline RHI and FBG at follow up, though for one study there was a 
statistical trend for a negative association (96), indicating that better endothelial function (higher 
values of RHI) were associated with lower (i.e., better) fasting blood glucose. Nonetheless, the 
beta coefficient of both cohorts indicated a negative relationship between baseline RHI and FBG 
at follow up, indicating that better endothelial function was associated with lower (i.e., better) 
fasting blood glucose. 
Only one study reported the relation between RHI and HbA1c (96), which showed no significant 
relationship between baseline RHI and HbA1c at follow up, Nonetheless, the beta coefficient 
indicated a negative relationship between baseline RHI and HbA1c, i.e., an increase in RHI value 
(better endothelial function) was related to decreased value of HbA1c (decrease chances of 
diabetes).  












Joris et al. 
(2017) (95) 
RHI FBG 26 -0.12 0.24 0.637 
Bredella et 
al.(2013) (96) 
RHI FBG 21 -0.39 0.02 0.090 
Bredella et 
al.(2013) (96) 
RHI HbA1c 21 -0.23 0.72 0.490 
* adjusted for age and sex, FBG: fasting blood glucose, FMD: flow mediated dilation, RHI: 





3.3.5. Flow mediated dilation and incidence of diabetes: 
The paper by Rossi et al. (94) evaluated the association between endothelial function (as reported 
through FMD values of the brachial artery) and the incidence of diabetes. 840 participants were 
divided into three tertiles of 280 participants each, based on their baseline FMD values. They 
were followed with regular intervals for almost 3.9 years (±0.7years). The tertile with highest 
values of FMD (i.e. the one with better endothelial function), was considered the reference for 
computing the relative risk (RR) of incident diabetes. As shown in table 4, the incidence of 
diabetes increased with worsening endothelial function (i.e., decreasing FMD values). Each one-
unit decrease of FMD (when examined as a continuous variable) was seen to cause a staggering 
32% (95% CI 22–48%) increase in the multiple-adjusted relative risk of incident diabetes. This 
data supports the hypothesis of poor endothelial function leading to the increased incidence of 
diabetes. 














Rossi et al. 
(94) 
1 FMD >5.6 280 1 1 9 
 2 4.4-5.5 280 2.85 2.14-5.10 35 
 3 FMD <4.3 280 5.4 3.35-7.99 58 
FMD: flow mediated dilation, C.I: confidence interval 
3.3.5. Quality assessment: 
Based on the relevant sections of the Newcastle-Ottawa scale, two studies were regarded as high 
quality (5 stars) (94, 96) and two as moderate quality (4 and 3 stars) (93, 95) (see Table 5). In 
three studies, representativeness of the exposed cohort did not meet the required criteria (zero 
stars). Our criteria of exposed cohort were populations with no NCDs, but these studies were 
selected from specific communities through local advertisement or targeted hospitals’ patient 
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records. Therefore, they were not truly representative of the average population with no NCDs. 
There was methodological heterogeneity in the selected studies as well, as all of them were not 
from the same study design. Two of the studies were randomized control trials (95, 96) and the 
other two studies were observational (93, 94). The representative sample of the quality 
assessment of all studies also got minimum score in the question of population selection because 
of the same reason. It is important to note that three (93, 95, 96) of the four studies were not 
designed to answer the primary question of this review hence the quality was estimated based on 
the basis of information available. 
Table 5: Quality assessment of selected articles using Newcastle-Ottawa scale for cohort 
studies  
 Joris et al. 
(95) 2017 





Rossi et al. 
(94) 2005 
Selection     
1. Representativeness 
of the exposed 
cohort  
0 star 0 star 1 star * 0 star 
2. Ascertainment of 
exposure 
1 star * 1 star * 0 star 1 star * 
3. Demonstration that 
outcome of interest 
was not present at 
start of study 
1 star * 1 star * 1 star * 1 star * 
Outcome     
1. Assessment of 
outcome 
1 star * 1 star * 1 star * 1 star * 
2. Was follow-up long 
enough for 
outcomes to occur 
0 star 1 star * 0 star 1 star * 
3. Adequacy of follow 
up of cohorts 
1 star * 1 star * 0 star 1 star * 







Three out of the four reviewed studies found no statistically significant associations between 
baseline endothelial function and diabetic status, though there was a trend between RHI and FBG 
in one study, indicating a negative association between RHI and FBG. However, one paper 
reported a significant negative association between FMD and the diagnosis of diabetes type II, 
i.e., individuals with worse endothelial function (denoted by smaller values of FMD) were more 
likely to develop diabetes. Collectively, these studies showed an association between endothelial 
function and incidence of diabetes but not with surrogate markers of diabetes. 
3.4.1. Endothelial function and incident diabetes: 
The association seen in the Rossi et al. (94) study is consistent with several studies that have 
used biomarker proxy-measures of endothelial function. For example, the nested case control 
study within the Nurses’ health study (97), the CARDIA study (98), the case-cohort study of 
KORA (99) and another longitudinal study (100), which all reported increased incidence of 
diabetes type II with endothelial dysfunction (when defined through increased biomarker of 
endothelial function). When comparing our results with these studies, it must be pointed out that 
their method of endothelial function measures was different from those within our review. 
Specifically, they used biomarker measures of endothelial function, which are a common 
invasive method of measuring endothelial function. However, caution is needed in interpreting 
these result as these biomarkers are not just the product of the endothelium but other 
physiological factors, such as inflammation (101).  
Other data support the potential link between endothelial function and the development of 
diabetes. Some studies have reported impaired FMD or decreased endothelial functions in first 
degree relatives of people with type II diabetes as compared to that of normal healthy people 
(102-104) and women with the history of gestational diabetes have also been found to have 
endothelial dysfunction (105-107). A weak but significant correlation between endothelial 
function and insulin sensitivity, in first degree relatives of diabetes, was also reported (108). 
Although these links are multifactorial, it does add to the data supporting an association between 
endothelial function and diabetes type II.  
3.4.2. Endothelial function and surrogate measures of diabetes: 
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While discussing the results of this systematic review, we cannot ignore the contrasting 
directionality reported by the studies for FMD and RHI. As per our hypothesis, the association 
between endothelial function and diabetes outcome should be negative, i.e. a smaller (poor) 
value of FMD or RHI would be associated with a bigger (worse) value of FBG or HbA1c. This 
inverse relationship is also reported in a number of previous studies (86, 109, 110). In our 
review, the selected studies reported positive direction of association for FMD and FBG, and 
negative association for RHI with FBG and HbA1c, except the population with history of 
preeclampsia of Ostlund (93) that reported negative association for FMD and FBG. Both FMD 
and RHI utilizes the mechanism of reactive hyperemia creating sheer stress in the arteries, but  
RHI measures changes in smaller resistances arteries (i.e., finger radial arteries) (25). According 
to Meigs, a gradual decline in endothelial function at the microvascular levels causes the 
progression of diabetes type II (71). Also, the drug intervention prescribed to lower the glucose 
levels in diabetic patients, lowers the risk of microvascular complications suggesting diabetes 
type II is manifested in the microvasculature (111).  This hypothesis gives a potential reason why 
we get the desired negative association for RHI and diabetes surrogate markers as RHI measurers 
changes in the micro-circulation.  
It must be noted that HbA1c is regarded as a more reliable marker for the diagnosis of diabetes 
than fasting blood glucose, as it represents an 8 weeks profile of serum glucose levels (85). 
Serum HbA1c was found to be associated with diabetes and other vascular complications in non-
diabetics as well (112). We conclude that this could be a potential reason that we did not see 
significant results with FBG. Another explanation for this non-significant result between 
endothelial function measures (FMD & RHI) and surrogate markers of diabetes can be explained 
with the possibility that this relationship is non-linear, and the poor endothelial function doesn’t 
follow a continuum. It implies that the effect of endothelial function getting impaired can take 
place or is not diagnosed until a certain threshold of FBG or HbA1c, after reaching that 
threshold, the increase in FBG does not correlate or show any difference in the endothelial 
function anymore, because it cannot  possibly get any worst. This physiological ‘breaking point’ 
can be explained with the example of smoking dose and effect on endothelial function. It was 
reported by this population-based study (113) that the prevalence of impaired FMD increases 
gradually in light smokers to heavy smokers. However, the prevalence rate increased two-fold 
for smokers who smoked 30 cigarettes/day and this rate remained the same for heavy smokers 
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(40 cigarettes/day) and chronic smokers (more than 40 cigarettes/day). This suggests that with 
heavy smoking (30 cigarettes/day), increasing the number of cigarettes wouldn’t affect the 
endothelial function anymore because the endothelial function reached its ‘breaking point’ after 
which it can’t get worse than its current impaired state and hence the prevalence rate become 
constant after a certain point.  
3.4.3. Potential mechanism linking endothelial dysfunction and diabetes: 
The endothelium is responsible for the transportation of micro and macro particles to and from 
capillaries, arteries and interstitial fluid (65). The manifestation of endothelial dysfunction at the 
capillary level decreases its surface area as well as diminishes vasodilatory responses to insulin 
in arterioles, contributing to insulin resistance. Therefore, delivery of the insulin products to the 
interstitial fluid is delayed. The vasodilatory action of insulin on the skeletal muscle is also 
mediated by endothelium dependent nitrous oxide (114). According to Reaven, insulin resistance 
is the originating point for the impaired hemodynamic and metabolic responses in the 
endothelium and hence insulin resistance is the precursor of  many vascular complications like 
hypertension, dyslipidemia and diabetes type II (66). Similarly, endothelial dysfunction occurs at 
different stages of neuropathy irrespective of serum glucose concentration (67). It causes the 
inhibition of some glycolytic enzymes that initiate various inflammatory pathways that can 
damage the peripheral nerve as well cause an imbalance between redox state and reactive oxygen 
species (ROS) (68) . It can be concluded that increased ROS and pro-inflammatory responses are 
responsible for diabetic neuropathy, caused due to endothelial dysfunction due to accumulation 
of  diacylglycerol (84). In another mechanism, the endothelial dysfunction of renal 
microcirculation leads to albuminuria in people without any diagnosed renal disease. 
Albuminuria was reported to be related to incidence of diabetes in men in the epidemiological 
study of insulin resistance syndrome(69). The author points out that the deficiency of endothelial 
protective factor, adiponectin is responsible for strong relationship of high albumin excretion rate 
with incident diabetes (115).  
It was also reported in drug trial studies that, pharmacological drugs like ramipril and pravastatin 
that are prescribed to improve endothelial function, also reduces the risk of diabetes type II (87). 
Other drugs like metformin or troglitazone prescribed for insulin sensitization in type II diabetics 
improves endothelial vasodilation by lowering the production of E-selectin (88, 116, 117). These 
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drugs reported to reduced the risk of diabetes incidence, when given to non diabetic patients 
(89). This parallel effect of drugs on both endothelial function and diabetes incidence shows a 
potential correlation between them. An inverse relationship between serum HbA1c and FMD 
was also reported by few studies in non-diabetic participants (85, 86, 109).  
3.4.4. Reverse causation: 
As per the scope of this systematic review, we explored the association of endothelial 
dysfunction as a risk factor for diabetes type II but the reverse direction of diabetes type II being 
a risk factor for endothelial dysfunction can’t be ignored. Endothelial function becomes the cause 
of many micro and macro vascular complications and diabetes type II is one of them. There are 
several mechanisms that are evident in both these conditions due to which researchers are unable 
to conclude whether endothelial dysfunction is a consequence or cause of diabetes type II. As 
mentioned above, inflammatory responses due to endothelial dysfunction increases the chances 
of micro-vascular complication with an increase in ROS levels, but in diabetes type II as well, an 
increase in inflammatory responses causes increased vascular permeability, vasoregulatory 
responses and thrombus formation that results in cell damage and endothelial dysfunction. (118, 
119). Some studies have shown that a hyperglycemic environment give rise to increased 
production of ROS. These molecules increase the intercellular gap formation causing impaired 
cell to cell adhesion thus increasing permeability. Increased permeability and ROS levels are also 
evidence of endothelial dysfunction (74). A reduced production of NO and lower bioavailability 
of NO translates to a dysfunctional endothelium. Lower production can be due to some mutation, 
co-factor or substrate deficiency and inflammatory response effects on the endothelium. All 
these findings from the literature point towards the possibility of endothelial dysfunction 
occurring as a consequence of diabetes, instead of vice versa as is hypothesized by us. Therefore, 
this relationship is also worth investigating. 
3.4.5. Strengths and limitations of our study 
3.4.51. Limitation in the literature:   
A key limitation of the literature is the lack of studies that reported direct relationship between 
endothelial function measures and measures of diabetes. Due to this fact we asked authors to 
provide analyses only adjusted for sex and age, but there are other factors that could have 
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influenced the result including BMI, smoking status and physical activity. As such, the 
correlations reported might not be accurate. Variability of the follow up time in the selected 
studies could also be one of the limitations in the studies as they can affect the conclusion 
inferred from it.  
3.4.52. Limitation in the Review: 
Out of the eligible 16 studies, we were able to include only four studies because neither the 
primary nor secondary objective of the article aligned with our research question. Our inclusion 
criteria included studies in English and French language, and we may have missed relevant 
studies published in other languages. The selected four studies had multiple sources of 
heterogeneity in it. Potential sources of heterogeneity were inclusion of only one sex in the 
population selection, different follow up times and different types of outcome measures. The 
variability of these factors among the original studies introduces clinical heterogeneity in this 
systematic review. Furthermore, this heterogeneity didn’t allow us to conduct a meta-analysis. 
3.4.53. Strength of the systematic review: 
The selected studies were of high (n=2) and moderate quality (n=2) as assessed by Newcastle 
Ottawa scale with relevant fields, translating into low risk of bias in the studies. Also, we have 
reported this systematic review according to the guidelines of PRISMA and the reader can access 
the checklist in the appendix 2. This transparency gives readers the liberty to contrast the 
conclusion based on the information reported and hence strengthen our review.  
3.4.6. Implication and future recommendation: 
This systematic review summarizes the longitudinal association between endothelial dysfunction 
and diabetes type II, which are two of the most prevalent and dangerous complications of human 
physiology, increasing the rate of morbidity and mortality in different populations around the 
globe (120-123). Based on this systematic review, we can say that more robust longitudinal 
studies involving healthy participants, are required in this area. Different studies have reported 
that timely diagnosis and treatment of endothelial dysfunction can lead to its reversal in certain 
populations and hence, can prevent future complications like diabetes type II and cardiovascular 
diseases (80, 124, 125). In this review, we have evaluated the association between endothelial 
function and diabetes type II in one direction. However, we have also identified possible 
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pathways for the reverse direction and there is a need for further exploration of the potential for 
diabetes type II leading to endothelial dysfunction (119, 126-128) Accurate establishment of this 
association can lead to exploring new avenues of prevention and treatment before the 
manifestation of diabetes or its related complications (129). 
Although many invasive and non-invasive methods are employed for endothelial function 
measurement, there is still a lack of a specific gold standard for its measurement. There is a need 
of a standardized and more reliable method of a prognostic test since earlier detection of 
endothelial dysfunction can help clinicians in taking timely steps for prevention and 
treatment. Also, for assessing the endothelial function, no simple screening technique has been 
developed until now that could be performed easily as a screening method in the healthcare 
settings. In the research setting, FMD is the method that is commonly deployed for the non-
invasive measurement of endothelial function but the absence of a set threshold value contrasting 
between good and bad endothelial function is still non-existent. This fact renders room for 
improvement in this area so that a standard or a scale can be developed for more reproducible 
findings. 
Though RHI is emerging as a new and reliable technique of assessing the endothelial function, 
the information on its performance is still limited (130). Since FMD and RHI measure different 
mechanisms of endothelial function, it is suggested that the assessment method must be utilized 
according to the function under examination (25). Future research focusing on intra- and inter-
observer reliability and reproducibility, test re-test reproducibility and factors affecting the 
measurement must be established for more reliable and robust studies on this longitudinal 
association utilizing non-invasive methods of assessment of endothelial function.  
3.5.Conclusion: 
In conclusion, this systematic review was not able to find strong, robust evidence of a 
longitudinal association between endothelial function and type II diabetes in healthy adults 
without any NCDs. There was one study that showed evidence of a negative association between 
endothelial function and incidence of diabetes, with worse endothelial function (denoted with 
smaller values of either FMD or RHI) being associated with an increase in the incidences of 
diabetes. There was no evidence of a longitudinal association between baseline endothelial 
function and surrogate markers of type II diabetes. It was difficult to arrive at a strong conclusion 
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due to the limited number of articles reporting longitudinal association between endothelial 
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 3.7.1.  Appendix 1: Instructions for Authors Cardiovascular Diabetology journal: 
Review 
Criteria 
Summaries of recent insights in specific research areas within the scope of Cardiovascular 
Diabetology. These articles should address a particular question or issue and provide an 
evidence-based and balanced approach on the focused topic. The reviews should include the 
description of how the relevant evidences were identified, assessed for quality, and selected for 
inclusion. Controversial aspects and unresolved issues should be discussed. Authors should 
justify in the cover letter their expertise in the target area, and also both the scientific relevance 
and the lack of recent reviews on the topic. Each manuscript should include up to 6 figures. 
Preparing your manuscript 
The information below details the section headings that you should include in your manuscript 
and what information should be within each section. 
Please note that your manuscript must include a 'Declarations' section including all of the 
subheadings (please see below for more information). 
Title page 
The title page should: 
present a title that includes, if appropriate, the study design e.g.: 
"A versus B in the treatment of C: a randomized controlled trial", "X is a risk factor for Y: a case 
control study", "What is the impact of factor X on subject Y: A systematic review" 
or for non-clinical or non-research studies: a description of what the article reports 
list the full names and institutional addresses for all authors 
if a collaboration group should be listed as an author, please list the Group name as an author. If 
you would like the names of the individual members of the Group to be searchable through their 
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individual PubMed records, please include this information in the “Acknowledgements” section 
in accordance with the instructions below 
indicate the corresponding author 
Abstract 
The Abstract should not exceed 350 words. Please minimize the use of abbreviations and do not 
cite references in the abstract. 
Keywords 
Three to ten keywords representing the main content of the article. 
Main text 
This should contain the body of the article, and may also be broken into subsections with short, 
informative headings.  
Conclusions 
This should state clearly the main conclusions and provide an explanation of the importance and 
relevance of the case, data, opinion, database or software reported. 
List of abbreviations 
If abbreviations are used in the text they should be defined in the text at first use, and a list of 
abbreviations should be provided. 
Declarations 
All manuscripts must contain the following sections under the heading 'Declarations': 
Ethics approval and consent to participate 
Consent for publication 







Authors' information (optional) 
Please see below for details on the information to be included in these sections. 
If any of the sections are not relevant to your manuscript, please include the heading and write 
'Not applicable' for that section.  
Ethics approval and consent to participate 
Manuscripts reporting studies involving human participants, human data or human tissue must: 
include a statement on ethics approval and consent (even where the need for approval was 
waived) 
include the name of the ethics committee that approved the study and the committee’s reference 
number if appropriate 
Studies involving animals must include a statement on ethics approval and for experimental 
studies involving client-owned animals, authors must also include a statement on informed 
consent from the client or owner. 
See our editorial policies for more information. 
If your manuscript does not report on or involve the use of any animal or human data or tissue, 
please state “Not applicable” in this section. 
Consent for publication 
If your manuscript contains any individual person’s data in any form (including any individual 
details, images or videos), consent for publication must be obtained from that person, or in the 
case of children, their parent or legal guardian. All presentations of case reports must have 
consent for publication. 
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You can use your institutional consent form or our consent form if you prefer. You should not 
send the form to us on submission, but we may request to see a copy at any stage (including after 
publication). 
See our editorial policies for more information on consent for publication. 
If your manuscript does not contain data from any individual person, please state “Not 
applicable” in this section. 
Availability of data and materials 
All manuscripts must include an ‘Availability of data and materials’ statement. Data availability 
statements should include information on where data supporting the results reported in the article 
can be found including, where applicable, hyperlinks to publicly archived datasets analysed or 
generated during the study. By data we mean the minimal dataset that would be necessary to 
interpret, replicate and build upon the findings reported in the article. We recognise it is not 
always possible to share research data publicly, for instance when individual privacy could be 
compromised, and in such instances data availability should still be stated in the manuscript 
along with any conditions for access. 
Data availability statements can take one of the following forms (or a combination of more than 
one if required for multiple datasets): 
The datasets generated and/or analysed during the current study are available in the [NAME] 
repository, [PERSISTENT WEB LINK TO DATASETS] 
The datasets used and/or analysed during the current study are available from the corresponding 
author on reasonable request. 
All data generated or analysed during this study are included in this published article [and its 
supplementary information files]. 
The datasets generated and/or analysed during the current study are not publicly available due 
[REASON WHY DATA ARE NOT PUBLIC] but are available from the corresponding author 
on reasonable request. 
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Data sharing is not applicable to this article as no datasets were generated or analysed during the 
current study. 
The data that support the findings of this study are available from [third party name] but 
restrictions apply to the availability of these data, which were used under license for the current 
study, and so are not publicly available. Data are however available from the authors upon 
reasonable request and with permission of [third party name]. 
Not applicable. If your manuscript does not contain any data, please state 'Not applicable' in this 
section. 
More examples of template data availability statements, which include examples of openly 
available and restricted access datasets, are available here. 
BioMed Central also requires that authors cite any publicly available data on which the 
conclusions of the paper rely in the manuscript. Data citations should include a persistent 
identifier (such as a DOI) and should ideally be included in the reference list. Citations of 
datasets, when they appear in the reference list, should include the minimum information 
recommended by DataCite and follow journal style. Dataset identifiers including DOIs should be 
expressed as full URLs. For example: 
 
Hao Z, AghaKouchak A, Nakhjiri N, Farahmand A. Global integrated drought monitoring and 
prediction system (GIDMaPS) data sets. figshare. 
2014. http://dx.doi.org/10.6084/m9.figshare.853801 
With the corresponding text in the Availability of data and materials statement: 
The datasets generated during and/or analysed during the current study are available in the 
[NAME] repository, [PERSISTENT WEB LINK TO DATASETS].[Reference number]  
If you wish to co-submit a data note describing your data to be published in BMC Research 
Notes, you can do so by visiting our submission portal. Data notes support open data and 
help authors to comply with funder policies on data sharing. Co-published data notes will be 
linked to the research article the data support (example). 
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For more information please email our Research Data Team. 
Competing interests 
All financial and non-financial competing interests must be declared in this section. 
See our editorial policies for a full explanation of competing interests. If you are unsure 
whether you or any of your co-authors have a competing interest please contact the editorial 
office. 
Please use the authors initials to refer to each authors' competing interests in this section. 
If you do not have any competing interests, please state "The authors declare that they have no 
competing interests" in this section. 
Funding 
All sources of funding for the research reported should be declared. The role of the funding body 
in the design of the study and collection, analysis, and interpretation of data and in writing the 
manuscript should be declared. 
Authors' contributions 
The individual contributions of authors to the manuscript should be specified in this section. 
Guidance and criteria for authorship can be found in our editorial policies. 
Please use initials to refer to each author's contribution in this section, for example: "FC analyzed 
and interpreted the patient data regarding the hematological disease and the transplant. RH 
performed the histological examination of the kidney, and was a major contributor in writing the 
manuscript. All authors read and approved the final manuscript." 
Acknowledgements 
Please acknowledge anyone who contributed towards the article who does not meet the criteria 
for authorship including anyone who provided professional writing services or materials. 




See our editorial policies for a full explanation of acknowledgements and authorship criteria. 
If you do not have anyone to acknowledge, please write "Not applicable" in this section. 
Group authorship (for manuscripts involving a collaboration group): if you would like the names 
of the individual members of a collaboration Group to be searchable through their individual 
PubMed records, please ensure that the title of the collaboration Group is included on the title 
page and in the submission system and also include collaborating author names as the last 
paragraph of the “Acknowledgements” section. Please add authors in the format First Name, 
Middle initial(s) (optional), Last Name. You can add institution or country information for each 
author if you wish, but this should be consistent across all authors. 
Please note that individual names may not be present in the PubMed record at the time a 
published article is initially included in PubMed as it takes PubMed additional time to code this 
information. 
Authors' information 
This section is optional. 
You may choose to use this section to include any relevant information about the author(s) that 
may aid the reader's interpretation of the article, and understand the standpoint of the author(s). 
This may include details about the authors' qualifications, current positions they hold at 
institutions or societies, or any other relevant background information. Please refer to authors 
using their initials. Note this section should not be used to describe any competing interests. 
Footnotes 
Footnotes can be used to give additional information, which may include the citation of a 
reference included in the reference list. They should not consist solely of a reference citation, and 
they should never include the bibliographic details of a reference. They should also not contain 
any figures or tables. 
Footnotes to the text are numbered consecutively; those to tables should be indicated by 
superscript lower-case letters (or asterisks for significance values and other statistical data). 
Footnotes to the title or the authors of the article are not given reference symbols. 
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Always use footnotes instead of endnotes. 
 
References 
Examples of the Vancouver reference style are shown below. 
See our editorial policies for author guidance on good citation practice 
Web links and URLs: All web links and URLs, including links to the authors' own websites, 
should be given a reference number and included in the reference list rather than within the text 
of the manuscript. They should be provided in full, including both the title of the site and the 
URL, as well as the date the site was accessed, in the following format: The Mouse Tumor 
Biology Database. http://tumor.informatics.jax.org/mtbwi/index.do. Accessed 20 May 
2013. If an author or group of authors can clearly be associated with a web link, such as for 
weblogs, then they should be included in the reference. 
Example reference style: 
Article within a journal 
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Article within a journal (no page numbers) 
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251-306. 
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3.7.2. Appendix 2: PRISMA checklist 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  13 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: background; objectives; data sources; study 
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key findings; systematic review registration number.  
14 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  16-17 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
17 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 




6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 




7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors 




Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it 




9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, 





10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) 
and any processes for obtaining and confirming data from investigators.  
19 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.  
19 
Risk of bias in 
individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of 
whether this was done at the study or outcome level), and how this information is to be used in any 




13 State the principal summary measures (e.g., risk ratio, difference in means).  n/a 
Synthesis of 
results  
14 Describe the methods of handling data and combining results of studies, if done, including measures 








Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, 




16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were pre-specified.  
n/a 
RESULTS   
Study 
selection  
17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 




18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-
up period) and provide the citations.  
21-22 
Risk of bias 
within studies  




20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for 




21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  n/a 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  n/a 
Additional 
analysis  
23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see 
Item 16]).  
n/a 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of evidence for each main outcome; consider their 
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Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete 
retrieval of identified research, reporting bias).  
31-32 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for 
future research.  
32-33 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of 




3.7.3. Appendix 3: Search strategy 
1. SEARCH STRATEGY PUBMED (11 NOV 2019): 
#34 Search (#33) NOT (#31) NOT (#32)) 4603 
#33 Search (#29) AND (#30)) 9962 
#32 Search (#27) OR #28 
312891
5 




Search ((((((((((((#11) OR #12) OR #13) OR #14) OR #15) OR #16) OR 
#17) OR #18) OR #19) OR #20) OR #21) OR #22) OR #23 313921 
#29 
Search ((((((((#1) OR #2) OR #3) OR #4) OR #5) OR #6) OR #7) OR #8) 
OR #9) OR #10 272264 
#28 Search review article 
312475
8 
#27 Search systematic review 161755 
#26 Search animal 
668726
8 
#25 Search animal study 
206305
6 
#24 Search animal model 773532 
#23 Search endothelial dysfunction 80443 
#22 Search endothelium dysfunction 41782 
#21 Search endothelial function 301588 
#20 Search endothelium function 133899 
#19 Search flow mediated dilation 6151 
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#18 Search FMD 7612 
#17 Search endo pat 53 
#16 Search finger plethysmography 1475 
#15 Search peripheral arterial tonometry 962 
#14 Search forearm hyperemic reactivity 33 
#13 Search flow mediated vasodilation 6524 
#12 Search flow mediated dilatation 2310 
#11 Search brachial artery reactivity 574 
#10 Search late onset diabetes 143161 
#9 Search HBA1C 51131 
#8 Search hyper glycaemia 43 
#7 Search hyperglycemia 69282 
#6 Search adult onset diabetes 150948 
#5 Search type 2 dm 10660 
#4 Search type 2 diabetes 172168 
#3 Search diabetes mellitus type II 150035 
#2 Search diabetes mellitus type 2 142751 




3.7.4. Appendix 4: Newcastle-Ottawa Quality Assessment Form for Cohort Studies 
 Newcastle-Ottawa Quality Assessment Form for Cohort Studies  
Note: A study can be given a maximum of one star for each numbered item within the Selection 
and Outcome categories. A maximum of two stars can be given for Comparability.  
Selection  
1) Representativeness of the exposed cohort  
a) Truly representative (one star)  
b) Somewhat representative (one star)  
c) Selected group  
d) No description of the derivation of the cohort  
2) Selection of the non-exposed cohort  
a) Drawn from the same community as the exposed cohort (one star)  
b) Drawn from a different source  
c) No description of the derivation of the non exposed cohort  
3) Ascertainment of exposure  
a) Secure record (e.g., surgical record) (one star)  
b) Structured interview (one star)  
c) Written self report  
d) No description  
e) Other  
4) Demonstration that outcome of interest was not present at start of study  
a) Yes (one star)  





1) Comparability of cohorts on the basis of the design or analysis controlled for confounders  
a) The study controls for age, sex and marital status (one star)  
b) Study controls for other factors (list) _________________________________ (one star)  
c) Cohorts are not comparable on the basis of the design or analysis controlled for confounders  
 
Outcome  
1) Assessment of outcome  
a) Independent blind assessment (one star)  
b) Record linkage (one star)  
c) Self report  
d) No description  
e) Other  
2) Was follow-up long enough for outcomes to occur  
a) Yes (one star)  
b) No  
 
Indicate the median duration of follow-up and a brief rationale for the assessment above: 
____________________  
3) Adequacy of follow-up of cohorts  
a) Complete follow up- all subject accounted for (one star)  
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b) Subjects lost to follow up unlikely to introduce bias- number lost less than or equal to 20% or 
description of those lost suggested no different from those followed. (one star)  
c) Follow up rate less than 80% and no description of those lost  
d) No statement 
 
Thresholds for converting the Newcastle-Ottawa scales to AHRQ standards (good, fair, and 
poor):  
Good quality: 3 or 4 stars in selection domain AND 1 or 2 stars in comparability domain AND 2 
or 3 stars in outcome/exposure domain  
Fair quality: 2 stars in selection domain AND 1 or 2 stars in comparability domain AND 2 or 3 
stars in outcome/exposure domain  
Poor quality: 0 or 1 star in selection domain OR 0 stars in comparability domain OR 0 or 1 stars 
in outcome/exposure domain 
